Johnson & Johnson (NYSE:JNJ) has reported new data from its Phase 3 Vivacity-MG3 trial showing that its therapy IMAAVY (nipocalimab-aahu) sustained disease control in adults with generalized myasthenia gravis over a follow-up period of up to 120 weeks.
The study followed 153 patients who tested positive for disease-related antibodies, including anti-AChR and anti-MuSK. At the 96-week mark in the open-label extension phase, patients treated with IMAAVY recorded average improvements of 6.47 points on the MG-ADL scale and 5.97 points on the QMG scale, both key measures of symptom severity and muscle function.
Around half of participants achieved minimal symptom expression, with nearly one-third maintaining this level for at least eight weeks. In addition, 57% of patients reduced corticosteroid use to 10 mg per day or less, while total immunoglobulin G levels fell by more than 64%.
A post-hoc analysis from the 24-week double-blind phase showed that patients receiving IMAAVY alongside standard treatment were four times more likely to reach sustained minimal symptom expression compared to those given a placebo. Those maintaining this level of disease control also reported greater improvements in quality of life.
“These long-term results, now extending to beyond two years, provide further evidence that disease control can be sustained,” said Constantine Farmakidis, Associate Professor of Neurology at the University of Kansas Medical Center.
Johnson & Johnson also confirmed that its EPIC trial—comparing IMAAVY with efgartigimod in patients who have not previously received an FcRn blocker—is currently enrolling participants.
The company presented the findings as part of seven abstracts at the American Academy of Neurology 2026 Annual Meeting in Chicago. IMAAVY is already approved for treating generalized myasthenia gravis in adults and in patients aged 12 and older who are positive for AChR or MuSK antibodies.